Clarus Therapeutics Holdings Inc

NASDAQ:CRXT   10:53:19 AM EDT
4.56
-0.16 (-3.39%)
Earnings Announcements

Clarus Therapeutics Q3 Revenue Rises 93% To $4.3 Mln

Published: 11/18/2021 21:56 GMT
Clarus Therapeutics Holdings Inc (CRXT) - Clarus Therapeutics Reports Third Quarter 2021 Financial and Operating Results.
Q3 Loss per Share $0.26.
Q3 Revenue Rose 93 Percent to $4.3 Million.
Q3 Earnings per Share View $-0.81, Revenue View $3.2 Million -- Refinitiv Ibes Data (analyst estimates).
Revenue is expected to be $4.64 Million
Adjusted EPS is expected to be -$0.68

Next Quarter Revenue Guidance is expected to be $4.3 Million
Next Quarter EPS Guidance is expected to be -$1.13

More details on our Analysts Page.